These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 33016857)

  • 1. Computational simulation studies on the binding selectivity of Wee1 and Checkpoint kinase 1 by molecular dynamics simulation combined with free energy calculations.
    Li Y; Liu X; Zhang S; Wang L; Zhang L; Zuo Z
    J Biomol Struct Dyn; 2022 Feb; 40(3):1172-1181. PubMed ID: 33016857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacophore modeling, multiple docking, and molecular dynamics studies on Wee1 kinase inhibitors.
    Hu Y; Zhou L; Zhu X; Dai D; Bao Y; Qiu Y
    J Biomol Struct Dyn; 2019 Jul; 37(10):2703-2715. PubMed ID: 30052133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined inhibition of Wee1 and Chk1 gives synergistic DNA damage in S-phase due to distinct regulation of CDK activity and CDC45 loading.
    Hauge S; Naucke C; Hasvold G; Joel M; Rødland GE; Juzenas P; Stokke T; Syljuåsen RG
    Oncotarget; 2017 Feb; 8(7):10966-10979. PubMed ID: 28030798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential properties of mitosis-associated events following CHK1 and WEE1 inhibitor treatments in human tongue carcinoma cells.
    Nojima H; Homma H; Onozato Y; Kaida A; Harada H; Miura M
    Exp Cell Res; 2020 Jan; 386(2):111720. PubMed ID: 31738907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Computational studies on the binding mechanism between triazolone inhibitors and Chk1 by molecular docking and molecular dynamics.
    Lv M; Ma S; Tian Y; Zhang X; Lv W; Zhai H
    Mol Biosyst; 2015 Jan; 11(1):275-86. PubMed ID: 25372494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimation of the ligand-binding free energy of checkpoint kinase 1 via non-equilibrium MD simulations.
    Mai NT; Lan NT; Vu TY; Duong PTM; Tung NT; Phung HTT
    J Mol Graph Model; 2020 Nov; 100():107648. PubMed ID: 32653524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined inhibition of Chk1 and Wee1: in vitro synergistic effect translates to tumor growth inhibition in vivo.
    Carrassa L; Chilà R; Lupi M; Ricci F; Celenza C; Mazzoletti M; Broggini M; Damia G
    Cell Cycle; 2012 Jul; 11(13):2507-17. PubMed ID: 22713237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 90-kDa heat shock protein inhibition abrogates the topoisomerase I poison-induced G2/M checkpoint in p53-null tumor cells by depleting Chk1 and Wee1.
    Tse AN; Sheikh TN; Alan H; Chou TC; Schwartz GK
    Mol Pharmacol; 2009 Jan; 75(1):124-33. PubMed ID: 18820127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacophore modeling, molecular docking and molecular dynamics simulations toward identifying lead compounds for Chk1.
    Li Y; Peng J; Zhou Y; Li P; Li Y; Liu X; Siddique AN; Zhang L; Zuo Z
    Comput Biol Chem; 2018 Oct; 76():53-60. PubMed ID: 29940486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo.
    Chaudhuri L; Vincelette ND; Koh BD; Naylor RM; Flatten KS; Peterson KL; McNally A; Gojo I; Karp JE; Mesa RA; Sproat LO; Bogenberger JM; Kaufmann SH; Tibes R
    Haematologica; 2014 Apr; 99(4):688-96. PubMed ID: 24179152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acquired small cell lung cancer resistance to Chk1 inhibitors involves Wee1 up-regulation.
    Zhao X; Kim IK; Kallakury B; Chahine JJ; Iwama E; Pierobon M; Petricoin E; McCutcheon JN; Zhang YW; Umemura S; Chen V; Wang C; Giaccone G
    Mol Oncol; 2021 Apr; 15(4):1130-1145. PubMed ID: 33320980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma.
    Chilà R; Basana A; Lupi M; Guffanti F; Gaudio E; Rinaldi A; Cascione L; Restelli V; Tarantelli C; Bertoni F; Damia G; Carrassa L
    Oncotarget; 2015 Feb; 6(5):3394-408. PubMed ID: 25428911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological inactivation of CHK1 and WEE1 induces mitotic catastrophe in nasopharyngeal carcinoma cells.
    Mak JP; Man WY; Chow JP; Ma HT; Poon RY
    Oncotarget; 2015 Aug; 6(25):21074-84. PubMed ID: 26025928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selected arylsulphonyl pyrazole derivatives as potential Chk1 kinase ligands-computational investigations.
    Czaja K; Kujawski J; Kamel K; Bernard MK
    J Mol Model; 2020 May; 26(6):144. PubMed ID: 32424505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural and energetic insights into the selective inhibition of PKMYT1 against WEE1.
    Qi X; Li G; Liu J; Mou L; Zhang Y; Guo S; Chen X; Li W
    J Biomol Struct Dyn; 2024 Apr; 42(6):3010-3018. PubMed ID: 37345529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological targeting the ATR-CHK1-WEE1 axis involves balancing cell growth stimulation and apoptosis.
    Mak JP; Man WY; Ma HT; Poon RY
    Oncotarget; 2014 Nov; 5(21):10546-57. PubMed ID: 25301733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of novel wee1 inhibitors via structure-based virtual screening and biological evaluation.
    Li Y; Pu Y; Liu H; Zhang L; Liu X; Li Y; Zuo Z
    J Comput Aided Mol Des; 2018 Sep; 32(9):901-915. PubMed ID: 30182144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of CHK1 and WEE1 as a new therapeutic approach in diffuse large B cell lymphomas with MYC deregulation.
    Restelli V; Vagni M; Arribas AJ; Bertoni F; Damia G; Carrassa L
    Br J Haematol; 2018 Apr; 181(1):129-133. PubMed ID: 28025833
    [No Abstract]   [Full Text] [Related]  

  • 19. Discovery and in silico evaluation of aminoarylbenzosuberene molecules as novel checkpoint kinase 1 inhibitor determinants.
    Singh R; Bhardwaj VK; Sharma J; Das P; Purohit R
    Genomics; 2021 Jan; 113(1 Pt 2):707-715. PubMed ID: 33065246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In silico and structure-based evaluation of deleterious mutations identified in human Chk1, Chk2, and Wee1 protein kinase.
    Colaco V; Goswami N; Goel VK; Srivastava SK; Lalrohlua P; Senthil Kumar N; Borah P; Baruah R; Varma AK
    J Cell Biochem; 2024 Jan; 125(1):89-99. PubMed ID: 38047473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.